Significant changes in macrophage and CD8 T cell densities in primary prostate tumors 2 weeks after SBRT

BACKGROUND: Radiotherapy impacts the local immune response to cancers. Prostate Stereotactic Body Radiotherapy (SBRT) is a highly focused method to deliver radiotherapy often used to treat prostate cancer. This is the first direct comparison of immune cells within prostate cancers before and after S...

Descripción completa

Detalles Bibliográficos
Autores principales: Kane, Nathanael, Romero, Tahmineh, Diaz-Perez, Silvia, Rettig, Matthew B., Steinberg, Michael L., Kishan, Amar U., Schaue, Dorthe, Reiter, Robert E., Knudsen, Beatrice S., Nickols, Nicholas G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10023555/
https://www.ncbi.nlm.nih.gov/pubmed/35058580
http://dx.doi.org/10.1038/s41391-022-00498-6
Descripción
Sumario:BACKGROUND: Radiotherapy impacts the local immune response to cancers. Prostate Stereotactic Body Radiotherapy (SBRT) is a highly focused method to deliver radiotherapy often used to treat prostate cancer. This is the first direct comparison of immune cells within prostate cancers before and after SBRT in patients. METHODS: Prostate cancers before and 2 weeks after SBRT are interrogated by multiplex immune fluorescence targeting various T cells and macrophages markers and analyzed by cell and pixel density, as part of a clinical trial of SBRT neoadjuvant to radical prostatectomy. RESULTS: Two weeks after SBRT, CD68, and CD163 macrophages are significantly increased while CD8 T cells are decreased. SBRT markedly alters the immune environment within prostate cancers.

Ejemplares similares